PT Kalbe Farma Tbk : Company Update FY 2025 Audited Results (07-April-2026)

About this update from Pt Kalbe Farma Tbk

Apr 2026 PT Kalbe Farma Tbk (KLBF IJ/KLBF.JK) Company Update FY25 1 1 YTD Dec 2025 Table of Contents Key Updates 04 Business Strategies 09 Financial Overview 24 Appendix 1 30 Appendix 2 36 3 Key Updates 4 Key updates Business Strategy Financial Updates Appendix I Appendix II ‌More than Half a Century of Providing Wide-Range Healthcare Solutions Corporate Overview Establishment 1966 IDX Listed 1991 7% International 34.5% Distribution & Logistics 22.8% Nutritionals 93% Domestic Prescription Pharmaceuticals Net Sales 29.0% IDR 35.3 tn 13.7% Consumer Health Market Capitalization* IDR 46.11 tn | USD 2.71 bn Free Float* 38.31% Treasury Shares* 3.34% *As of 31 Mar '26 Free FloaT is calculaTed as ToTal shares deducTed by The majoriTy, boards, Treasury and scripT shares 5 Key updates Business Strategy Financial Updates Appendix I Appendix II Solid Fundamentals for Future Growth Key Takeaways 8.3% 13.1% net sales growth net profit growth Key Updates Positive organic top-line growth driven by volume Margin improvement Marketing investment to sustain growth Progressing on track in key projects to drive future growth Key Challenges Pressure on purchasing power in domestic market Exchange rate fluctuation amidst geopolitics and trade war Strategic Partnerships and Investments Strengthening product portfolio through collaboration Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients Radiopharmaceuticals facilities (cyclotron) Biologic products' commercialization Strategic Partnership with Alliance Pharma Co.,Ltd. to penetrate the Thai market Moving towards local manufacturing of medical equipment 6

View stock analysis, news, and events for Pt Kalbe Farma Tbk